ESC 365 - PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event

HFA Premium Access

PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event

Session: Late breaking clinical trials: medical therapy

Topic: Pharmacotherapy

Speaker: Doctor R. Mentz (Durham, US)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

10 presentations

0 follower

4 more presentations in this session

A pre-specified, participant-level pooled analysis of PARAGON-HF and PARAGLIDE-HF

Speaker: Doctor M. Vaduganathan (Boston, US)

STEP HFpEF trial design and baseline characteristics

Speaker: Doctor M. Kosiborod (Kansas City, US)

DAPA-RESIST clinical trial - Dapagliflozin versus metolazone in heart failure with diuretic resistance

Speaker: Doctor R. Campbell (Glasgow, GB)

Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial

Speaker: Professor A. Voors (Groningen, NL)

Access the full session

Late breaking clinical trials: medical therapy

Speakers: Doctor R. Mentz, Doctor M. Vaduganathan, Doctor M. Kosiborod, Doctor R. Campbell, Professor A. Voors

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources